UroGen Pharma Ltd.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Quarterly earnings reports show how the company is performing financially, helping investors track growth and profitability.
Earnings announcements let investors see the company's latest revenue, profit, and other important financial metrics.
Director elections and governance changes affect how the company is run and who makes decisions.
Resolving lawsuits and licensing deals affect the company's future revenue from its drug Jelmyto.
Quarterly earnings reports show how the company is performing financially, helping investors track growth and profitability.
Earnings announcements let investors see the company's latest revenue, profit, and other important financial metrics.
Annual reports show complete financial performance and explain how the company is governed.
Stocky reads UroGen Pharma Ltd.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
UroGen Pharma Ltd.'s most recent tracked filing was a 10-Q on 5 Aug 2026: Reports Q2 2026 financial results for six months ended June 30.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.